High Hopes For Merck/AiCuris Late-Stage CMV Candidate Despite Chimerix Failure
This article was originally published in Scrip
Executive Summary
Chimerix Inc.'s dramatic Phase III flop of its oral antiviral brincidofovir in human cytomegalovirus (HCMV) was not a disappointment to everyone. Merck & Co. Inc. and its little-known German partner AiCuris, which have Phase III data due later this year on their oral product letermovir (AIC246), suddenly found themselves in the lead with a very promising next-generation candidate for the treatment of HCMV.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.